• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

神经病变型戈谢病:在西方罕见,在东方常见。

Neuronopathic Gaucher disease: Rare in the West, common in the East.

机构信息

Lysosomal and Rare Disorder Research and Treatment Center, Fairfax, Virginia, USA.

出版信息

J Inherit Metab Dis. 2024 Sep;47(5):917-934. doi: 10.1002/jimd.12749. Epub 2024 May 20.

DOI:10.1002/jimd.12749
PMID:38768609
Abstract

Gaucher disease (GD) stands as one of the most prevalent lysosomal disorders, yet neuronopathic GD (nGD) is an uncommon subset characterized by a wide array of clinical manifestations that complicate diagnosis, particularly when neurological symptoms are understated. nGD may manifest as the acute neuronopathic type, or GD type 2 (GD2), either prenatally or within the first weeks to months of life, whereas GD type 3 (GD3) symptoms may emerge at any point during childhood or occasionally in adolescence. The clinical presentation encompasses severe systemic involvement to mild visceral disease, often coupled with a spectrum of progressive neurological signs and symptoms such as cognitive impairment, ataxia, seizures, myoclonus, varying degrees of brainstem dysfunction presenting with stridor, apneic episodes, and/or impaired swallowing. This manuscript aims to provide a comprehensive review of the incidence, distinctive presentations, and diverse clinical phenotypes of nGD across various countries and regions. It will explore the natural history of the neurodegenerative process in GD, shedding light on its various manifestations during infancy and childhood, and offer insights into the diagnostic journey, the challenges faced in the clinical management, and current and investigative therapeutic approaches for GD's neurological variants.

摘要

戈谢病(Gaucher disease,GD)是最常见的溶酶体贮积症之一,而神经病变型戈谢病(neuronopathic Gaucher disease,nGD)则是一种不常见的亚型,具有广泛的临床表现,这使得诊断变得复杂,尤其是当神经系统症状被低估时。nGD 可表现为急性神经病变型,即 GD 型 2(GD2),可在产前或生命的最初几周至几个月内出现,而 GD 型 3(GD3)的症状可能在儿童期的任何时候出现,偶尔也会在青春期出现。临床表现包括严重的全身性受累和轻度内脏疾病,常伴有一系列进行性神经系统症状和体征,如认知障碍、共济失调、癫痫发作、肌阵挛、不同程度的脑干功能障碍,表现为喘鸣、呼吸暂停发作和/或吞咽困难。本文旨在全面回顾不同国家和地区 nGD 的发病率、独特表现和不同的临床表型。它将探讨 GD 神经退行性过程的自然史,阐明其在婴儿期和儿童期的各种表现,并深入了解诊断过程、临床管理中面临的挑战,以及当前和探索性的 GD 神经病变治疗方法。

相似文献

1
Neuronopathic Gaucher disease: Rare in the West, common in the East.神经病变型戈谢病:在西方罕见,在东方常见。
J Inherit Metab Dis. 2024 Sep;47(5):917-934. doi: 10.1002/jimd.12749. Epub 2024 May 20.
2
Diagnosing neuronopathic Gaucher disease: New considerations and challenges in assigning Gaucher phenotypes.诊断神经病变型戈谢病:戈谢表型分类的新考虑因素和新挑战。
Mol Genet Metab. 2021 Feb;132(2):49-58. doi: 10.1016/j.ymgme.2021.01.002. Epub 2021 Jan 9.
3
A Brazilian Rare-Disease Center's Experience with Glucosylsphingosine (lyso-Gb1) in Patients with Gaucher Disease: Exploring a Novel Correlation with IgG Levels in Plasma and a Biomarker Measurement in CSF.巴西一家罕见病中心对戈谢病患者使用葡萄糖神经酰胺(溶血神经酰胺1)的经验:探索与血浆中IgG水平的新关联以及脑脊液中的生物标志物测量
Int J Mol Sci. 2024 Mar 1;25(5):2870. doi: 10.3390/ijms25052870.
4
The D409H variant in GBA1: Challenges in predicting the Gaucher phenotype in the newborn screening era.GBA1 中的 D409H 变异:在新生儿筛查时代预测戈谢病表型的挑战。
Am J Med Genet A. 2023 Jul;191(7):1783-1791. doi: 10.1002/ajmg.a.63202. Epub 2023 Apr 12.
5
Challenges in Gaucher disease: Perspectives from an expert panel.戈谢病的挑战:专家小组观点
Mol Genet Metab. 2025 May;145(1):109074. doi: 10.1016/j.ymgme.2025.109074. Epub 2025 Mar 10.
6
Gaucher Disease Diagnosis Using Lyso-Gb1 on Dry Blood Spot Samples: Time to Change the Paradigm?戈谢病的干血斑样本中溶酶体β-葡糖苷酶 1 检测诊断:是时候改变现状了吗?
Int J Mol Sci. 2022 Jan 30;23(3):1627. doi: 10.3390/ijms23031627.
7
Development and evaluation of a patient-reported outcome measure specific for Gaucher disease with or without neurological symptoms in Japan.在日本,开发并评估了一种用于伴有或不伴有神经症状的戈谢病的患者报告结局测量工具。
Orphanet J Rare Dis. 2024 Jan 5;19(1):11. doi: 10.1186/s13023-023-02996-9.
8
A Drosophila Model of Neuronopathic Gaucher Disease Demonstrates Lysosomal-Autophagic Defects and Altered mTOR Signalling and Is Functionally Rescued by Rapamycin.一种神经元型戈谢病的果蝇模型显示溶酶体自噬缺陷、mTOR信号改变,且雷帕霉素可对其进行功能挽救。
J Neurosci. 2016 Nov 16;36(46):11654-11670. doi: 10.1523/JNEUROSCI.4527-15.2016.
9
Type 2 Gaucher disease: 15 new cases and review of the literature.2型戈谢病:15例新病例及文献综述。
Brain Dev. 2006 Jan;28(1):39-48. doi: 10.1016/j.braindev.2005.04.005.
10
Clinical and preclinical insights into high-dose ambroxol therapy for Gaucher disease type 2 and 3: A comprehensive systematic review.临床和临床前对高剂量安布罗洛治疗戈谢病 2 型和 3 型的深入了解:全面的系统评价。
Mol Genet Metab. 2024 Sep-Oct;143(1-2):108556. doi: 10.1016/j.ymgme.2024.108556. Epub 2024 Jul 31.

引用本文的文献

1
Base and translation of β-glucocerebrosidase and its transporter LIMP-2 in neuropathies.β-葡萄糖脑苷脂酶及其转运体LIMP-2在神经病变中的基础与翻译
Neural Regen Res. 2026 Jan 1;21(1):314-315. doi: 10.4103/NRR.NRR-D-24-01056. Epub 2025 Jan 13.
2
Gaucher disease in Brazil: a comprehensive 16 year retrospective study on survival, cost, and treatment insights.巴西的戈谢病:一项关于生存、成本及治疗见解的16年综合回顾性研究
Front Pharmacol. 2024 Sep 26;15:1433970. doi: 10.3389/fphar.2024.1433970. eCollection 2024.